DENKHAUS DONALD A 4
4 · CATALYST PHARMACEUTICALS, INC. · Filed Jan 10, 2025
Insider Transaction Report
Form 4
DENKHAUS DONALD A
Director
Transactions
- Exercise/Conversion
Common Stock, par value $0.001 per share
2025-01-08$2.24/sh+50,000$112,000→ 491,079 total - Exercise/Conversion
Options to purchase common stock
2025-01-08−50,000→ 162,274 totalExercise: $2.24Exp: 2025-12-19→ Common Stock (50,000 underlying)
Footnotes (1)
- [F1]Derivative securities vested in three equal tranches on December 19, 2019, 2020 and 2021.